Institutional investors purchased a net $3.4 million shares of GEVA during the quarter ended December 2012. This may signal that the smart money is gaining interest in this company as the 94.15% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
| Other institutional | 48.36% |
| Mutual fund holders | 45.79% |
| Individual stakeholders | 10.73% |